The Australian subsidiary of CSL Behring is set to develop a plasma-derived therapeutic for the treatment of serious complications in Covid-19 patients.
The company intends to focus on patients whose infection is progressing to the requirement for ventilation. Named Covid-19 Immunoglobulin, the therapeutic will be developed by CSL Behring Australia at its manufacturing facility in Broadmeadows, Victoria.
The first part of the development project will involve production and use of a small batch of Covid-19 Immunoglobulin to create tests for detecting the presence of the antibodies against SARS-CoV-2, the novel coronavirus that causes Covid-19.